[New results concerning the effectiveness of therapy of chronic glomerulonephritis. Results of cytostatics-anticoagulants-aggregation inhibitors, cystostatics-anticoagulants-aggregation inhibitors-prednisone and cystostatics-prednisone therapy, derived from a retrospective study].
The indication and effectiveness of the immunosuppressive therapy of chronic glomerulonephritis is now as ever controversial. As a result of a retrospective therapy study in an at least one-year therapy with cytostatics, thrombocyte aggregation inhibitors and anticoagulants (CAA-therapy, n = 27), additional prednisone therapy (CAAP-therapy, n = 95) and cytostatic-prednisone therapy (CP-therapy, n = 33) we find favourable results for the CAA/CAAP-therapy in the nephrotic syndrome and glomerulonephritides with distinct clinical exacerbation also in sclerosations in histology. Clinically inactive nephritides with exclusive urinary findings and sclerosations cannot be influenced therapeutically.
D000925:Anticoagulants / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D010974:Platelet Aggregation / Q000187:drug effects; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D002699:Chlorambucil; D011241:Prednisone
Neue Ergebnisse zur Effektivität der Therapie der chronischen Glomerulonephritis. Resultate der Zytostatika-Antikoagulantien-Aggregationshemmer (ZAA)-, Zytostatika-Antikoagulantien-Aggregationshemmer-Prednison (ZAAP)- und Zytostatika-Prednison (ZP)-Therapie im Ergebnis einer retrospektiven Studie.